ERBB2 and neoplasm: In addition, higher levels of tumor-infiltrating lymphocytes (TILs), another important participant in antitumor immunity, were significantly associated with decreased distant recurrence in patients with HER2-positive breast cancer treated with the anti-HER2 monoclonal antibody, trastuzumab [13].